TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06792253
Drug: Gemcitabine Hydrochloride for Injection
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine Hydrochloride for Injection,dosage of administration:1g/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Study: NCT06792253
Drug: Oxaliplatin Injection
Normalized name: oxaliplatin Injection
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Study: NCT06792253
Drug: Etoposide Injection
Normalized name: etoposide Injection
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on days 1,2,and 3 of each cycle, with a 21-day cycle duration.
Study: NCT06792253
Drug: Ifosfamide for Injection
Normalized name: Ifosfamide for Injection
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide for Injection,dosage of administration:5000mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Study: NCT06792253
Drug: Carboplatin Injection
Normalized name: Carboplatin Injection
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin Injection,,dosage of administration:single dose ≤800 mg (calculated based on AUC=5),frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Study: NCT06739551
Drug: Acitretin
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral acitretin 50 mg once daily for 12 weeks
Study: NCT05411146
Drug: [14C]-etrumadenant
DrugBank: Etrumadenant (DB17506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT06736938
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1% is infused intravenously, initially at a bolus dose of 0.5 mg/kg followed by a maintenance dose in a continuous infusion of 0.5-1.0 mg/kg/hour.
Study: NCT06736938
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam is administered intravenously at an initial dose of 2 mg, as a bolus, followed by aliquots of 0.5 mg or 1 mg.
Study: NCT06736938
Drug: Pethidine
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine (100 mg/2 ml) is administered intravenously at a dosage of 0.5 mg/kg.
Study: NCT05204290
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be delivered at the discretion of the patient's medical oncologist within 6 weeks after finishing SBRT. If a patient is already receiving pembrolizumab at the time of enrollment, then SBRT should not start sooner than 5 days after the last pembrolizumab infusion.
Study: NCT06794775
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant monotherapy with Nivolumab
Study: NCT06794775
Drug: Nivolumab + Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjuvant combination therapy with Nivolumab and Ipilimumab
Study: NCT05726786
Drug: Immunonutrition
Normalized name: Ensure Surgery Immunonutrition Vanilla
DrugBank: Vanilla (DB10576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.~IN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag
Study: NCT06793514
Drug: Probiotic
Normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium infantis, Streptococcus thermophiles) alongside with fructooligosaccharide (FOS), which is prepared in the concentration of 109 cfu by Bisot Khimr and is in the form of an edible sachet that can be dissolved in cold water, which is consumed once a day for one month. Sachets should be stored at a temperature of 2 to 8 degrees Celsius (in the refrigerator), which increases the useful life of probiotic bacteria and makes them more effective.
Study: NCT06124417
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dose ranged from 25 to 50 mg, taken orally once daily, and the dosage was adjusted based on the patient's response to the medication.
Study: NCT04812808
Drug: Bazedoxifene 20 mg
Normalized name: bazedoxifene 20 MG
DrugBank: Bazedoxifene (DB06401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bazedoxifene will be administered during the duration of the study in the experimental arm together with chemotherapy.~Prophylactic rivaroxaban (Xarelto®) 10 mg per day orally will be added to avoid thromboembolic events.
Study: NCT05224609
Drug: Lorlatinib
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single 100mg oral dose anti-cancer agent
Study: NCT05567510
Drug: BMS-986369
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05291338
Drug: Lipiodol
Normalized name: Lipiodol
DrugBank: Ethiodized oil (DB00965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol dose should be over 5 ml if tumor diameter is less than 5 cm, and the maximum dose will be 10 ml when the tumor develops to more than 5 cm in diameter.
Study: NCT06797518
Drug: Iptacopan
Normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNP023 oral capsule 200 mg b.i.d
Study: NCT06789016
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
Study: NCT06789016
Drug: 0.9%NaCl
Normalized name: triamcinolone acet/0.9%NaCl/PF 40 mg/mL INJECTION VIAL (ML)
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
Study: NCT06786624
Drug: NBI-1065845
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBI-1065845 tablets
Study: NCT04782258
Drug: Tolvaptan Suspension
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age.
Study: NCT04782258
Drug: Tolvaptan Tablets
Normalized name: Tolvaptan Tablets
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
Study: NCT05822583
Drug: abatacept infusion
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of abatacept will be 10 mg/kg given as a single infusion on Day 0, with a maximum dose of 1,750 mg, so any participant with weight of \>175 kg will receive a dose of 1750 mg. + baseline IM (immune modulator)
Study: NCT06471361
Drug: Zilucoplan
Normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.
Study: NCT05503797
Drug: Plixorafenib
Normalized name: Lifirafenib
DrugBank: Lifirafenib (DB14773)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT05503797
Drug: Cobicistat
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablets
Study: NCT05120505
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients in this group will be obtain Metformin starting from 50mg everyday at night, and gradually increase to maximum tolerable dose of 1-2g per day according to weights of patients for 6 months.
Study: NCT06745076
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06745076
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04816071
Drug: Essential amino acids
Normalized name: essential amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Supplement
Study: NCT05933044
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemoradiotherapy plus durvalumab
Study: NCT06372574
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 8 mg/kg IV will be administered to patients when necessary to treat potential cytokine release syndrome (CRS), as described in the protocol.
Study: NCT05803382
Drug: BET Bromodomain Inhibitor ZEN-3694
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05188664
Drug: LM-302
Normalized name: LM-030
DrugBank: LM-030 (DB18283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。
Study: NCT05188664
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.
Study: NCT05894837
Drug: Serplulimab+Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Serplulimab: once every two weeks; Regorafenib: from the first day to the 21st day
Study: NCT06795009
Drug: Zanzalintinib
Normalized name: Zanzalintinib
DrugBank: Zanzalintinib (DB17525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken by mouth.
Study: NCT06795009
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg\^m2 intravenous over 3 hours.
Study: NCT04983888
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1g IV on day one and 1 g IV on day 15, followed by identical course at month 6
Study: NCT04966702
Drug: Albendazole Pill
Normalized name: albendazole Pill
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using a MDA approach, fieldworkers will administer albendazole using directly observed treatment methodology to participants
Study: NCT04966702
Drug: Ivermectin Pill
Normalized name: ivermectin Pill
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using a MDA approach, fieldworkers will administer ivermectin using directly observed treatment methodology to participants
Study: NCT04966702
Drug: Ivermectin Injectable Product
Normalized name: ivermectin Injectable Product
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Veterinary ivermectin injectable will be given to livestock in the relevant cluster
Study: NCT06582264
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic
Study: NCT04931979
Drug: Pembrolizumab Injection [Keytruda]
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Up to 17 cycles of pembrolizumab until disease progression, toxicity, death, or withdrawal of IC (whichever occurs first)
Study: NCT05155332
Drug: BI 1831169
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1831169
Study: NCT05155332
Drug: anti-PD-1 antibody
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 antibody
Study: NCT04774380
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive durvalumab via IV infusion on Day 1 of each cycle.
Study: NCT04774380
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive cisplatin via IV administration on Day 1 of each cycle.
Study: NCT04774380
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive carboplatin via IV administration Day 1 of each cycle.
Study: NCT04774380
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.
Study: NCT05751343
Drug: TACE-HACI, plus atezolizumab-bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab
Study: NCT05588609
Drug: Afatinib Oral Tablet
Normalized name: afatinib Oral Tablet
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: anti epidermal growth factor receptor (EGFR)/HER2 agent
Study: NCT05588609
Drug: Enzalutamide Pill
Normalized name: enzalutamide Pill
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: second-generation androgen receptor antagonist
Study: NCT05588609
Drug: Abiraterone acetate tablets
Normalized name: Abiraterone Acetate Tablets
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: androgen synthesis inhibitor
Study: NCT06435442
Drug: Epaminurad
Normalized name: Epaminurad
DrugBank: Epaminurad (DB18973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epaminurad
Study: NCT06435442
Drug: Epaminurad placebo
DrugBank: Epaminurad (DB18973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epaminurad placebo
Study: NCT06201611
Drug: Nebivolol+ Standard care arm
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This arm will receive tablet Nebivolol 2.5 mg OD uptitrated at 2 weeks to 5 mg and at 4 weeks if well tolerated to 10 mg/day which the participant will continue upto week 24
Study: NCT06201611
Drug: Epalrestat + Alpha Lipoic Acid +Standard care
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will receive tablet Epalrestat -150mg OD+ cap Alpha Lipoic Acid 600mg OD for 24 weeks.
Study: NCT04952129
Drug: Selenomethionine
Normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Seleno-amino acid
Study: NCT04952129
Drug: Methylselenocysteine
Normalized name: methylselenocysteine
DrugBank: Methylselenocysteine (DB12697)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seleno-amino acid
Study: NCT03260972
Drug: Chloroprocaine Hcl 2% Inj
Normalized name: CHLOROPROCAINE HCL 2% INJ
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
Study: NCT04111627
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.
Study: NCT05564130
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate 1 mmol/ml
Study: NCT05564130
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride 9 mg/mL
Study: NCT06090669
Drug: imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib at 100-400 mg PO QD based on arm assignment/dose level
Study: NCT06343402
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive IV pembrolizumab
Study: NCT05613842
Drug: Copper-64 labelled SAR-Bombesin
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.
Study: NCT06325605
Drug: Bifidobacterium
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules, 3 times a day, for 8 consecutive weeks
Study: NCT06325605
Drug: Escitalopram Oxalate
Normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral escitalopram oxalate. The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks
Study: NCT05751941
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily
Study: NCT05751941
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160 mg of Enzalutamide will be given orally daily ending at week 4
Study: NCT05751941
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg of Apalutamide will be given orally daily ending at week 4
Study: NCT05751941
Drug: Sipuleucel-T
Normalized name: Sipuleucel-T
DrugBank: Sipuleucel-T (DB06688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
Study: NCT05789615
Drug: Letermovir
Normalized name: Letermovir
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Letermovir has achieved excellent therapeutic benefits globally but is still in its infancy in China. Letermovir obtained an implied license for a clinical trial in June 2020, and in November 2020, Letermovir submitted and accepted four new drug marketing applications in China, including injection and tablet formulations. On December 31, 2021, the China National Medical Products Administration (NMPA) approved letermovir for cytomegalovirus (CMV) seropositive adult recipients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) \[R+\] prevention of cytomegalovirus infection and cytomegalovirus disease. The commercial launch of letermovir is estimated to be in August 2022.
Study: NCT05372354
Drug: CC-92480
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05372354
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05372354
Drug: BMS-986158
Normalized name: BMS-986158
DrugBank: BMS-986158 (DB15435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05372354
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05372354
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06717347
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06717347
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06745973
Drug: EPI-003
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion.
Study: NCT06287398
Drug: Epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epcoritamab (Epcor) is a bispecific antibody recognizing the T-cell antigen CD3 and the B-cell antigen CD20. Epcor is a supplied as a concentrate for solution for intended subcutaneous injection. The dose must be prepared by a qualified pharmacist using aseptic technique.~Epcoritamab-Salvage treatment phase:~2-3 cycles of R-DHAOx therapy (rituximab, dexamethasone, cytarabine, oxaliplatin), given every 21 days combined with Epcoritamab subcutaneous weekly dosing (priming 0.16mg Cycle 1 Day 1, intermediate 0.8mg cycle 1 day 8, full dose 48mg from cycle 1 day 15 onwards)~Epcoritamab Consolidation phase:~6 cycles (28 days each) of subcutaneous Epcoritamab, commencing between 6-12 weeks post ASCT.~Epcoritamab dosing and timing for consolidation:~* Cycle 1 Day 1: Priming (0.16mg) dose~* Cycle 1 Day 8: intermediate (0.8mg) dose~* Cycle 1 Day 15: full dose 48mg~* Cycle 1 Day 22, Cycle 2-3 Days 1, 8, 15 and 22: 48mg~* Cycles 4 to 6 - Days 1 and 15 (fortnightly dosing): 48mg
Study: NCT06742710
Drug: Liraglutide and metformin
Normalized name: Liraglutide
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide 3.0 mg or maximum tolerable dose/day × 12 weeks and metformin 1500 mg/day until pregnancy.